Type
1.
Käser M, Kenu E, Nyarko KM, Seefeld L, Ganu V, Lartey M, et al. Risk factors for Buruli ulcer in Ghana case control study in the Suhum-Kraboa-Coaltar and Akuapem South Districts of the Eastern Region. PLoS neglected tropical diseases [Internet]. 2014;8(11):e3279. Available from: http://www.plosntds.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pntd.0003279&representation=PDF
Type
1.
Trubiano J, Lavender C, Fyfe J, Bittmann S, Johnson P. The incubation period of Buruli ulcer (Mycobacterium ulcerans infection). PLoS neglected tropical diseases [Internet]. 2013;7(10):e2463. Available from: http://www.plosntds.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pntd.0002463&representation=PDF
Type
1.
Bretzel G, Adjei O, Fleischer B, Sarfo FS, Phillips RO, Herbinger K-H, et al. Effectiveness of routine BCG vaccination on Buruli ulcer disease: A case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS neglected tropical diseases [Internet]. 2015;9(1):11 p. Available from: http://www.plosntds.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pntd.0003457&representation=PDF
Type
1.
Phanzu DM, Suykerbuyk P, Saunderson P, Ngwala Lukanu P, Masamba Minuku J-B, Imposo DB, et al. Burden of Mycobacterium ulcerans disease (Buruli Ulcer) and the underreporting ratio in the territory of Songololo, Democratic Republic of Congo. PLoS neglected tropical diseases [Internet]. 2013;7(12):e2563. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855042/pdf/pntd.0002563.pdf
Type
1.
Phillips, Sarfo, Abass, Abotsi, Wilson, Forson, et al. Clinical and bacteriological efficacy of Rifampin-Streptomycin combination for two weeks followed by Rifampin and Clarithromycin for six weeks for treatment of mycobacterium ulcerans disease. Antimicrobial agents and chemotherapy. 2014;58(2):1161-6.
Type
1.
Hamzat T, Boakye-Afram B. Health-related quality of life among persons living with buruli ulcer in amasaman community, Ga west district Accra, Ghana. International journal of health sciences [Internet]. 2011;5(1):29-38. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312766/pdf/ijhs5_1p029.pdf
Type
1.
Jansson M, Beissner M, Phillips RO, Badziklou K, Piten E, Maman I, et al. Molecular determination of Rifampicin resistance in clinical samples of patients with buruli ulcer disease: A comparison of two assays. Journal of clinical microbiology [Internet]. 2014; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993512/pdf/zjm1246.pdf
Type
1.
Kpadonou T, Houngbédji G, Alagnidé E, Gouton E, Azanmasso H, Niama D, et al. Health-related quality of life of adult patients healed from Buruli ulcer in Benin. British Journal of Medicine and Medical Research. 2015;6(1):88-9.
Type
1.
Andreoli A, Ruf M-T, Sopoh GE, Schmid P, Pluschke G. Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients. PLoS neglected tropical diseases [Internet]. 2014;8(4):e2809. Available from: http://www.plosntds.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pntd.0002809&representation=PDF
Type
1.
Sambourg, Dufour, Edouard, Morris, Mosnier, Reynaud, et al. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana]. Ann Dermatol Venereol. 2014;141(6-7):413-8.
Pagination
- Previous page
- Page 13
- Next page